Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ascletis Pharma, Inc. ( (HK:1672) ) has issued an announcement.
Ascletis Pharma Inc. has announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, for clinical development targeting obesity. The preclinical studies indicate that ASC36 offers a significantly longer half-life and greater weight reduction compared to existing treatments, positioning it as a potentially best-in-class therapy. The company plans to submit an Investigational New Drug Application to the FDA by the second quarter of 2026, which could enhance its market positioning in the obesity treatment sector.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$12.84 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biotechnology company focused on developing innovative treatments for metabolic diseases, including obesity. The company utilizes advanced technologies such as Artificial Intelligence-Assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform to create novel therapeutic solutions.
Average Trading Volume: 9,112,144
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.16B
See more data about 1672 stock on TipRanks’ Stock Analysis page.